Compare ACXP & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACXP | SOBR |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.3M |
| IPO Year | 2021 | 2008 |
| Metric | ACXP | SOBR |
|---|---|---|
| Price | $5.65 | $0.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $95.50 | N/A |
| AVG Volume (30 Days) | ★ 6.2M | 151.1K |
| Earning Date | 03-13-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.19 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $212,736.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.29 | $0.46 |
| 52 Week High | $8.34 | $7.70 |
| Indicator | ACXP | SOBR |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 41.98 |
| Support Level | $3.44 | $0.67 |
| Resistance Level | $7.15 | $1.03 |
| Average True Range (ATR) | 0.95 | 0.11 |
| MACD | 0.39 | 0.04 |
| Stochastic Oscillator | 69.33 | 34.33 |
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.